286 related articles for article (PubMed ID: 21471647)
1. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
Schulz JB; Rainer M; Klünemann HH; Kurz A; Wolf S; Sternberg K; Tennigkeit F
J Alzheimers Dis; 2011; 25(3):463-75. PubMed ID: 21471647
[TBL] [Abstract][Full Text] [Related]
2. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
3. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease.
Weiner MW; Sadowsky C; Saxton J; Hofbauer RK; Graham SM; Yu SY; Li S; Hsu HA; Suhy J; Fridman M; Perhach JL
Alzheimers Dement; 2011 Jul; 7(4):425-35. PubMed ID: 21646051
[TBL] [Abstract][Full Text] [Related]
5. Memantine in moderate-to-severe Alzheimer's disease.
Reisberg B; Doody R; Stöffler A; Schmitt F; Ferris S; Möbius HJ;
N Engl J Med; 2003 Apr; 348(14):1333-41. PubMed ID: 12672860
[TBL] [Abstract][Full Text] [Related]
6. Memantine and functional communication in Alzheimer's disease: results of a 12-week, international, randomized clinical trial.
Saxton J; Hofbauer RK; Woodward M; Gilchrist NL; Potocnik F; Hsu HA; Miller ML; Pejović V; Graham SM; Perhach JL
J Alzheimers Dis; 2012; 28(1):109-18. PubMed ID: 21955815
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
[TBL] [Abstract][Full Text] [Related]
9. Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study.
Holthoff V; Ferris S; Gauthier S; Ihl R; Robert P; Winblad B; Sternberg K; Tennigkeit F;
Int J Geriatr Psychiatry; 2013 Feb; 28(2):164-72. PubMed ID: 22492589
[TBL] [Abstract][Full Text] [Related]
10. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
Pomara N; Ott BR; Peskind E; Resnick EM
Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
[TBL] [Abstract][Full Text] [Related]
11. A 6-month, open-label study of memantine in patients with frontotemporal dementia.
Diehl-Schmid J; Förstl H; Perneczky R; Pohl C; Kurz A
Int J Geriatr Psychiatry; 2008 Jul; 23(7):754-9. PubMed ID: 18213609
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD.
Hellweg R; Wirth Y; Janetzky W; Hartmann S
Int J Geriatr Psychiatry; 2012 Jun; 27(6):651-6. PubMed ID: 22513699
[TBL] [Abstract][Full Text] [Related]
13. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
14. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients.
Ferris S; Ihl R; Robert P; Winblad B; Gatz G; Tennigkeit F; Gauthier S
Alzheimers Dement; 2009 Sep; 5(5):369-74. PubMed ID: 19751915
[TBL] [Abstract][Full Text] [Related]
15. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
Gauthier S; Loft H; Cummings J
Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.
Jones RW; Bayer A; Inglis F; Barker A; Phul R
Int J Geriatr Psychiatry; 2007 Mar; 22(3):258-62. PubMed ID: 17243195
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
19. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
Reisberg B; Doody R; Stöffler A; Schmitt F; Ferris S; Möbius HJ
Arch Neurol; 2006 Jan; 63(1):49-54. PubMed ID: 16401736
[TBL] [Abstract][Full Text] [Related]
20. Memantine enhances autonomy in moderate to severe Alzheimer's disease.
Rive B; Vercelletto M; Damier FD; Cochran J; François C
Int J Geriatr Psychiatry; 2004 May; 19(5):458-64. PubMed ID: 15156547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
